The ReSViNET Foundation is the international leading non-profit organization committed to reducing the global burdens of RSV infection. RSV acute lower respiratory infection (ALRI) is one of our most significant global healthcare challenges, not only in infants, but also in older adults and no vaccine is licensed for prevention. It is already affecting 33.1 million children under 5 years worldwide.
Since the inception in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest developments and reports on groundbreaking studies and in this way helping to move the field forward.
In the past years ReSViNET has built strong partnerships with many stakeholders. We aim to foster global collaboration among researchers, the health sector, governments, international statutory bodies, non-profit organisations and the wider civil society in an effort to coordinate actions and raise awareness about RSV infection and to tackle the challenge of RSV infection prevention and treatment.
ReSViNET Foundation brings together the necessary and complementary components, e.g. RSV expertise, research leadership and knowledge, patients and operational quality with the ultimate aim of reducing global child morbidity and mortality. The Scientific board includes investigators in the field of Respiratory Syncytial Virus (RSV) infections from Australia, Argentina, Brazil, South-Africa, the European Union, the United Kingdom and The United States.
It will take a concerted global effort to tackle RSV and we are looking forward to continue and advance our collaborations and partnerships with global leaders, WHO, BMGF, RSV society (ISIRV), PATH, EMA, FDA, pharmaceutical companies, patients and other parties within the RSV community to stimulate development of new therapeutics.
ReSViNET Scientific Board